$PHIO
Phio Pharmaceuticals Corp

2014 Q4 Form 10-Q Financial Statement

#000119312514410208 Filed on November 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $10.00K $16.00K $92.00K
YoY Change -66.67% -82.61% 61.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $760.0K $770.0K $930.0K
YoY Change -31.53% -17.2% 72.22%
% of Gross Profit
Research & Development $1.560M $1.459M $1.229M
YoY Change 8.33% 18.71% 1.24%
% of Gross Profit
Depreciation & Amortization $20.00K $30.00K $30.00K
YoY Change 0.0% 0.0% -25.0%
% of Gross Profit
Operating Expenses $2.320M $2.225M $2.163M
YoY Change -9.02% 2.87% 23.39%
Operating Profit -$2.209M -$2.071M
YoY Change 6.66% 22.11%
Interest Expense $0.00 $4.000K $10.00K
YoY Change -100.0% -60.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $3.000K $2.000K
YoY Change 50.0% -96.23%
Pretax Income -$2.300M -$2.210M -$2.060M
YoY Change -8.37% 7.28% 25.61%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.300M -$2.206M -$2.059M
YoY Change -8.37% 7.14% 25.24%
Net Earnings / Revenue -23000.0% -13787.5% -2238.04%
Basic Earnings Per Share
Diluted Earnings Per Share -$715.2M -$913.7M -$1.658B
COMMON SHARES
Basic Shares Outstanding 21.13M shares 16.10M shares 11.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.500M $10.13M $15.85M
YoY Change -40.93% -36.09% 152.39%
Cash & Equivalents $8.496M $5.130M $6.847M
Short-Term Investments $0.00 $5.000M $9.000M
Other Short-Term Assets $490.0K $560.0K $230.0K
YoY Change 40.0% 143.48% 21.05%
Inventory
Prepaid Expenses $442.0K
Receivables
Other Receivables
Total Short-Term Assets $8.988M $10.69M $16.08M
YoY Change -39.04% -33.52% 148.36%
LONG-TERM ASSETS
Property, Plant & Equipment $183.0K $193.0K $130.0K
YoY Change 3.39% 48.46% -44.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.00K $18.00K $0.00
YoY Change 0.0%
Total Long-Term Assets $201.0K $211.0K $130.0K
YoY Change 3.08% 62.31% -45.15%
TOTAL ASSETS
Total Short-Term Assets $8.988M $10.69M $16.08M
Total Long-Term Assets $201.0K $211.0K $130.0K
Total Assets $9.189M $10.90M $16.21M
YoY Change -38.49% -32.76% 141.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $285.0K $137.0K $177.0K
YoY Change 74.85% -22.6% 14.19%
Accrued Expenses $1.002M $958.0K $1.018M
YoY Change -44.18% -5.89% 16.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.334M $1.156M $1.342M
YoY Change -35.74% -13.86% -4.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.334M $1.156M $1.342M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.330M $1.160M $1.342M
YoY Change -35.93% -13.56% -4.89%
SHAREHOLDERS EQUITY
Retained Earnings -$46.88M -$44.58M
YoY Change 23.11%
Common Stock $2.000K $2.000K $1.000K
YoY Change 100.0% 100.0% -93.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.745M $4.723M $7.048M
YoY Change
Total Liabilities & Shareholders Equity $9.189M $10.90M $16.21M
YoY Change -38.49% -32.76% 141.52%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$2.300M -$2.206M -$2.059M
YoY Change -8.37% 7.14% 25.24%
Depreciation, Depletion And Amortization $20.00K $30.00K $30.00K
YoY Change 0.0% 0.0% -25.0%
Cash From Operating Activities -$1.600M -$1.760M -$1.730M
YoY Change 14.29% 1.73% 38.4%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$20.00K -$10.00K
YoY Change -85.71% 100.0%
Acquisitions
YoY Change
Other Investing Activities $5.000M -$5.000M $0.00
YoY Change -16.39% -100.0%
Cash From Investing Activities $4.990M -$5.010M -$10.00K
YoY Change -15.71% 50000.0% -150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.00K 0.000 -10.00K
YoY Change -200.0% -100.0% 0.0%
NET CHANGE
Cash From Operating Activities -1.600M -1.760M -1.730M
Cash From Investing Activities 4.990M -5.010M -10.00K
Cash From Financing Activities -30.00K 0.000 -10.00K
Net Change In Cash 3.360M -6.770M -1.750M
YoY Change -26.15% 286.86% 41.13%
FREE CASH FLOW
Cash From Operating Activities -$1.600M -$1.760M -$1.730M
Capital Expenditures -$10.00K -$20.00K -$10.00K
Free Cash Flow -$1.590M -$1.740M -$1.720M
YoY Change 19.55% 1.16% 37.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21132021 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.40
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1582211 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6847000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.41
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21132021 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2987264 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21132021 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1156000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
137000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44578000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
958000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
4723000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10901000
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47452000
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
61000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5130000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
193000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
510000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2014Q3 us-gaap Assets
Assets
10901000
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
5000000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
10690000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5127000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11788045 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11788045 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2556269 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2076000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.47
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
163000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38082000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1795000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
4942000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14938000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40969000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
118000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11390000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
303000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2013Q4 us-gaap Assets
Assets
14938000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
3000000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
14743000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7627 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.05
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4909000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.033 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9783615 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.64
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26546938 shares
us-gaap Revenue From Grants
RevenueFromGrants
370000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
5000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9000000
us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
12000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18431000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14000
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25810000
us-gaap Net Income Loss
NetIncomeLoss
-18417000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
78000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-371000
us-gaap Operating Expenses
OperatingExpenses
18801000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16213000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1720000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
7393000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15639000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15651000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
12250000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
396000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
251000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
36000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9010000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
510000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2588000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-239000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
7393000
us-gaap Share Based Compensation
ShareBasedCompensation
1506000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
dei Trading Symbol
TradingSymbol
RXII
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0150 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.46
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6163000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
430995 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Uses of Estimates in Preparation of Financial Statements</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14726417 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M22D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.99
dei Entity Central Index Key
EntityCentralIndexKey
0001533040
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19735374 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Revenue From Grants
RevenueFromGrants
57000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
5000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
207000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6520000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
15000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
10000
us-gaap Net Income Loss
NetIncomeLoss
-6496000
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
3000000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10164000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
68000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-57000
us-gaap Operating Expenses
OperatingExpenses
6577000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4118000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6260000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
3668000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1977000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1947000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
30000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3582000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-837000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
71000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2074000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
3000000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
477000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2459000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3668000
us-gaap Share Based Compensation
ShareBasedCompensation
1402000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0730 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.24
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0175 pure
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11630189 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0730 pure
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
92000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2071000
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3506000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-2059000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2163000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1229000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
934000
CY2013Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1447000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
449000
CY2013Q3 rxii Issuance Of Stock Options For Services
IssuanceOfStockOptionsForServices
7600
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0347 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.71
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0252 pure
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17494109 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0347 pure
CY2014Q3 us-gaap Revenue From Grants
RevenueFromGrants
16000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2209000
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2906000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-2206000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
2225000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1459000
CY2014Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
24000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
766000
CY2014Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
700000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
454000

Files In Submission

Name View Source Status
0001193125-14-410208-index-headers.html Edgar Link pending
0001193125-14-410208-index.html Edgar Link pending
0001193125-14-410208.txt Edgar Link pending
0001193125-14-410208-xbrl.zip Edgar Link pending
d801705d10q.htm Edgar Link pending
d801705dex311.htm Edgar Link pending
d801705dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20140930.xml Edgar Link completed
rxii-20140930.xsd Edgar Link pending
rxii-20140930_cal.xml Edgar Link unprocessable
rxii-20140930_def.xml Edgar Link unprocessable
rxii-20140930_lab.xml Edgar Link unprocessable
rxii-20140930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending